Order Tirzepatide in 30 and 40 mg online at Invus Labs. See prices and stock status. For laboratory research only, not for human use.

30 mg · SEK 999
All peptides · Shipping and delivery
Tirzepatide is a modified peptide containing 39 amino acids. Its structure and catalog quantity labels help distinguish molecular identity from a particular product pack.
Tirzepatide has a modified GIP-based peptide sequence with an attached fatty-acid moiety. Its scientific description therefore covers both the amino-acid chain and the chemical modification.
Tirzepatide is described as a dual agonist at GIP and GLP-1 receptors. This describes one molecule with two receptor targets, rather than two peptides mixed in a pack.
Retatrutide and Tirzepatide are distinct substances. Retatrutide is also described in relation to the glucagon receptor, whereas the dual-agonist description of Tirzepatide refers to GIP and GLP-1.
The stated mg quantity is a separate product characteristic. It does not specify a solution concentration or establish that different peptides are interchangeable in an assay.
Its modified peptide chain contains 39 amino acids and has an attached fatty-acid moiety.
No. Dual agonist describes two receptor targets for the molecule. A blend contains multiple separately named components.
Listed variants: 30 mg / 40 mg. The quantity belongs to each product variant; current availability is shown in the variant selector.
Tirzepatide, LY3298176 and the short name tirze belong to one catalog entry.
A number on a label and a number in a research paper can describe entirely different things.
Tirzepatide (LY3298176) acts at two receptors, the GIP receptor and the GLP-1 receptor.
The role of peptide materials in laboratory research.
How molecular identity and mass are examined in analytical work.
For laboratory research only. Not for human or veterinary use.